Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)

Reports Q4 revenue $169k, consensus $266.67k. “Our team has made tremendous progress recently in the global Phase 2 B-SUPREME study of pevifoscorvir sodium,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics (ALGS). “With the completion of the planned enrollment in the HBeAg- cohort, we are continuing to enroll participants in the HBeAg+ cohort and look forward to the interim analyses in the first and second half of 2026. Additionally, the Phase 2 B-SUPREME study may demonstrate that pevifoscorvir sodium affects the three pillars of HBV disease pathogenesis: replication, integration, and maintenance of the viral reservoir. We are also excited to announce the advancement, in partnership with Xiamen Amoytop Biotech Co., of ALG-170675, a dual mechanism antisense oligonucleotide into IND-enabling studies. Lastly, adding James Hassard as Executive Vice President, Chief Commercial Officer has allowed us to begin laying the groundwork for the future of our best-in-class programs.”